Ginkgo Bioworks Holdings Inc [NYSE: DNA] plunged by -$0.04 during the normal trading session on Friday and reaching a high of $1.40 during the day while it closed the day at $1.30. The company report on January 15, 2024 at 7:00 AM that Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world.
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric’s global network .
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
Ginkgo Bioworks Holdings Inc stock has also loss -15.03% of its value over the past 7 days. However, DNA stock has declined by -19.75% in the 3 months of the year. Over the past six months meanwhile, it has lost -36.27% and lost -23.08% year-on date.
The market cap for DNA stock reached $2.60 billion, with 1.34 billion shares outstanding and 1.32 billion shares in the current float. Compared to the average trading volume of 20.09M shares, DNA reached a trading volume of 23529411 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ginkgo Bioworks Holdings Inc [DNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $3.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 3.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 14, 2023.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.11, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 8.25. The Price to Book ratio for the last quarter was 1.92, with the Price to Cash per share for the same quarter was set at 0.53.
DNA stock trade performance evaluation
Ginkgo Bioworks Holdings Inc [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.03. With this latest performance, DNA shares dropped by -2.26% in over the last four-week period, additionally sinking by -36.27% over the last 6 months – not to mention a drop of -23.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 34.69, with the RSI for the last a single of trading hit 25.41, and the three-weeks RSI is set at 39.65 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 1.4938, while it was recorded at 1.4240 for the last single week of trading, and 1.6568 for the last 200 days.
Ginkgo Bioworks Holdings Inc [DNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ginkgo Bioworks Holdings Inc [DNA] shares currently have an operating margin of -452.56 and a Gross Margin at +44.35. Ginkgo Bioworks Holdings Inc’s Net Margin is presently recorded at -440.63.
Return on Total Capital for DNA is now -114.71, given the latest momentum, and Return on Invested Capital for the company is -114.49. Return on Equity for this stock declined to -129.87, with Return on Assets sitting at -91.31. When it comes to the capital structure of this company, Ginkgo Bioworks Holdings Inc [DNA] has a Total Debt to Total Equity ratio set at 25.49. Additionally, DNA Total Debt to Total Capital is recorded at 20.31, with Total Debt to Total Assets ending up at 17.43. Long-Term Debt to Equity for the company is recorded at 23.80, with the Long-Term Debt to Total Capital now at 18.97.
Reflecting on the efficiency of the workforce at the company, Ginkgo Bioworks Holdings Inc [DNA] managed to generate an average of -$1,629,202 per employee. Receivables Turnover for the company is 4.08 with a Total Asset Turnover recorded at a value of 0.21.Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.78 and a Current Ratio set at 6.78.
Earnings per share (EPS) analysis for Ginkgo Bioworks Holdings Inc [DNA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 31.70%.
Ginkgo Bioworks Holdings Inc [DNA]: Institutional Ownership
The top three institutional holders of DNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DNA stock with ownership which is approximately 5.8325%.
